阿那白滞素治疗家族性地中海热:单中心经验
治疗后发作频率下降,75例患者无发作,视觉模拟量表(VAS)评分从7.49(2.03)降至3.08(2.82)(P=0.001)。结论认为阿那白滞素对秋水仙碱难治性患者有效且安全。
要点
- 秋水仙碱难治性FMF患者使用阿那白滞素后发作频率下降,75例无发作。
- VAS评分从7.49(2.03)降至3.08(2.82),P=0.001。
- 34例(32%)停药,最常见原因为反应不足和副作用,副作用均可逆。
核心结论
- 在秋水仙碱难治性FMF患者中,抗IL-1药物阿那白滞素被显示有效且安全。
- 阿那白滞素的有效性来自预防发作和提高生活质量。
研究设计与样本
- 研究为单中心经验性回顾,在擅长自身炎症性疾病的三级风湿病中心开展。
- 纳入至少接受阿那白滞素治疗1个月的FMF患者,排除淀粉样变性和妊娠患者。
主要发现
- 45.92%的患者携带纯合M694V突变;98例接受MEFV检测的患者中83例携带至少一个M694V拷贝。
- 阿那白滞素治疗期间发作频率下降,75例患者无发作。
- VAS评分从7.49(2.03)降至3.08(2.82)(P=0.001)。
- 目前71例仍在接受阿那白滞素治疗,34例(32%)停药。
- 停药最常见原因为反应不足和副作用;观察到4例白细胞减少,所有副作用均可逆,停药后缓解。
关键数值与推荐
- VAS评分从7.49(2.03)降至3.08(2.82),P=0.001。
- 98例接受MEFV检测的患者中83例携带至少一个M694V拷贝。
- 45.92%的患者携带纯合M694V突变。
- 34例(32%)停用阿那白滞素。
临床怎么用
- 对秋水仙碱反应不足的FMF患者,可考虑使用阿那白滞素以降低发作频率和改善生活质量。
- 治疗期间需监测副作用,包括白细胞减少,停药后副作用可逆。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anakinra is proven to be effective in controlled trials in terms of attack frequency and subclinical inflammation in colchicine-resistant patients. The objective of this study was to review the patients followed in our single centre with FMF who received anakinra because of insufficient colchicine response. METHODS: The study was conducted at a tertiary rheumatology centre experienced in autoinflammatory diseases. The patients were treated for at least 1 month with anakinra. Patients with amyloidosis and pregnancy were not included. Attack frequency, patient global assessment scales of disease severity and acute phase reactants were recorded before and throughout anakinra treatment. Criteria of treatment termination were side effects, disease remission, inadequate response, pregnancy plan and non-compliance. RESULTS: One hundred and six patients diagnosed with FMF were treated with anakinra; 45.92% of the patients had a homozygous M694V mutation; 83 of the 98 patients tested for MEFV carried at least one copy of M694V. Attack frequency decreased while on anakinra treatment; in fact, no attacks were observed in 75 patients. Visual analogue scale score decreased from 7.49 (2.03) to 3.08 (2.82) (P = 0.001). Currently, 71 patients are still on anakinra treatment. Treatment of 34 patients was discontinued (32%). Insufficient response and side effects were the most common reasons for treatment discontinuation. All of the side effects observed were reversible and the patients alleviated after treatment cessation. In four patients, leukopenia was observed. CONCLUSION: In patients who were refractory to colchicine, anti-IL-1 agent anakinra was shown to be effective and safe. The effectiveness of anakinra stems from preventing attacks and increasing the quality of life.
引用
- Ugurlu S, Ergezen B, Egeli BH, et al. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. Rheumatology (Oxford). 2021. PMID: 33295622. doi:10.1093/rheumatology/keaa596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。